Regen BioPharma, Inc. (RGBP)
USD 0.05
(-12.78%)
USD 0.05
(-12.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.45 Million USD | -36.5% |
| 2022 | 8.59 Million USD | -41.52% |
| 2021 | 14.69 Million USD | 97.07% |
| 2020 | 7.45 Million USD | -32.25% |
| 2019 | 11 Million USD | 17.98% |
| 2018 | 9.33 Million USD | 50.6% |
| 2017 | 6.19 Million USD | 583.64% |
| 2016 | 906.25 Thousand USD | 185.31% |
| 2015 | 317.63 Thousand USD | 126.42% |
| 2014 | 140.28 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.4 Million USD | -1.04% |
| 2024 Q2 | 5.31 Million USD | -1.56% |
| 2024 Q3 | 5.32 Million USD | 0.21% |
| 2023 Q2 | 5.33 Million USD | 0.71% |
| 2023 Q1 | 5.29 Million USD | -38.35% |
| 2023 FY | 5.45 Million USD | -36.5% |
| 2023 Q4 | 5.45 Million USD | 2.7% |
| 2023 Q3 | 5.31 Million USD | -0.42% |
| 2022 Q1 | 10.49 Million USD | -28.62% |
| 2022 Q2 | 77.38 Million USD | 637.57% |
| 2022 Q4 | 8.59 Million USD | -4.92% |
| 2022 FY | 8.59 Million USD | -41.52% |
| 2022 Q3 | 9.03 Million USD | -88.32% |
| 2021 Q3 | 11.96 Million USD | 128.05% |
| 2021 Q2 | 5.24 Million USD | -8.43% |
| 2021 Q1 | 5.73 Million USD | -23.15% |
| 2021 Q4 | 14.69 Million USD | 22.79% |
| 2021 FY | 14.69 Million USD | 97.07% |
| 2020 FY | 7.45 Million USD | -32.25% |
| 2020 Q1 | 7.74 Million USD | -29.68% |
| 2020 Q2 | 11.83 Million USD | 52.93% |
| 2020 Q3 | 8.65 Million USD | -26.89% |
| 2020 Q4 | 7.45 Million USD | -13.82% |
| 2019 FY | 11 Million USD | 17.98% |
| 2019 Q3 | 12.9 Million USD | 45.5% |
| 2019 Q2 | 8.86 Million USD | 0.23% |
| 2019 Q4 | 11 Million USD | -14.67% |
| 2019 Q1 | 8.84 Million USD | -5.19% |
| 2018 FY | 9.33 Million USD | 50.6% |
| 2018 Q4 | 9.33 Million USD | 2.16% |
| 2018 Q3 | 9.13 Million USD | -4.8% |
| 2018 Q1 | 8.94 Million USD | 44.45% |
| 2018 Q2 | 9.59 Million USD | 7.21% |
| 2017 FY | 6.19 Million USD | 583.64% |
| 2017 Q4 | 6.19 Million USD | 24.3% |
| 2017 Q3 | 4.98 Million USD | 141.71% |
| 2017 Q1 | 862.77 Thousand USD | -4.8% |
| 2017 Q2 | 2.06 Million USD | 139.01% |
| 2016 Q2 | 448.25 Thousand USD | 31.75% |
| 2016 FY | 906.25 Thousand USD | 185.31% |
| 2016 Q1 | 340.22 Thousand USD | 7.11% |
| 2016 Q4 | 906.25 Thousand USD | 20.5% |
| 2016 Q3 | 752.05 Thousand USD | 67.77% |
| 2015 Q4 | 317.63 Thousand USD | 118.64% |
| 2015 Q2 | 180.07 Thousand USD | -44.75% |
| 2015 Q1 | 325.91 Thousand USD | 132.32% |
| 2015 Q3 | 145.28 Thousand USD | -19.32% |
| 2015 FY | 317.63 Thousand USD | 126.42% |
| 2014 Q1 | 16.42 Thousand USD | 0.0% |
| 2014 Q2 | 7597.00 USD | -53.75% |
| 2014 Q3 | 57.46 Thousand USD | 656.35% |
| 2014 FY | 140.28 Thousand USD | 0.0% |
| 2014 Q4 | 140.28 Thousand USD | 144.15% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -19794.346% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 42.345% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.469% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -574.784% |
| Rebus Holdings, Inc. | 5.24 Million USD | -4.113% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.752% |
| Qrons Inc. | 1.48 Million USD | -266.6% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -345.079% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.715% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12110.524% |
| Skye Bioscience, Inc. | 14.07 Million USD | 61.217% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.762% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 43.043% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1194.599% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.093% |
| Intellipharmaceutics International Inc. | 12 Million USD | 54.553% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -41.704% |
| Mesoblast Limited | 188.44 Million USD | 97.104% |
| Marizyme, Inc. | 26.67 Million USD | 79.541% |
| Genus plc | 485 Million USD | 98.875% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 6.59% |
| Pharming Group N.V. | 244.07 Million USD | 97.764% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -171.506% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -116.888% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -43.621% |
| ContraFect Corporation | 32.53 Million USD | 83.223% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -175.455% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -42.584% |
| IMV Inc. | 37.93 Million USD | 85.612% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 53.663% |
| MultiCell Technologies, Inc. | 1617.67 USD | -337275.114% |
| ONE Bio Corp. | 27.49 Million USD | 80.151% |
| Accustem Sciences Inc. | 1.07 Million USD | -405.691% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.95% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -158.035% |
| Q BioMed Inc. | 8.13 Million USD | 32.895% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.419% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -6.055% |
| Biomind Labs Inc. | 1.49 Million USD | -264.178% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.403% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 39.643% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 70.345% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -280.624% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3740.822% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2613.666% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 5.016% |
| GB Sciences, Inc. | 5.41 Million USD | -0.739% |
| Alpha Cognition Inc. | 7.16 Million USD | 23.827% |
| HST Global, Inc. | 593.59 Thousand USD | -819.421% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -333.422% |
| Halberd Corporation | 728.71 Thousand USD | -648.933% |
| Enzolytics Inc. | 365.26 Million USD | 98.506% |
| Agentix Corp. | 2.51 Million USD | -117.387% |
| Resverlogix Corp. | 67.39 Million USD | 91.902% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -550.698% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.773% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -218.414% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 77.945% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 54.15% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -48.905% |
| AVAX Technologies, Inc. | 3.99 Million USD | -36.654% |
| Zenith Capital Corp. | 27.56 Thousand USD | -19696.206% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.588% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2186.832% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -46.148% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -701.607% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -101.266% |
| Kadimastem Ltd | 3.5 Million USD | -55.715% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8054.337% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.142% |
| BioStem Technologies, Inc. | 15.9 Million USD | 65.685% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1074.441% |
| LadRx Corporation | 2.2 Million USD | -148.014% |
| Cell Source, Inc. | 15.8 Million USD | 65.473% |
| Regen BioPharma, Inc. | 5.45 Million USD | 0.0% |
| NovAccess Global Inc. | 7.86 Million USD | 30.571% |
| Affymax, Inc. | 8.87 Million USD | 38.478% |
| Itoco Inc. | 1.65 Million USD | -230.134% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -166.022% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 9.777% |
| Mobile Lads Corp. | 1.31 Million USD | -315.503% |
| CytoDyn Inc. | 127.89 Million USD | 95.733% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -12956.81% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -248.423% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 50.589% |
| SYBLEU INC | 681.41 Thousand USD | -700.926% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 10.559% |
| International Stem Cell Corporation | 5.27 Million USD | -3.423% |
| Bioxytran, Inc. | 3.24 Million USD | -67.952% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -772.09% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -18.204% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 86.687% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 75.488% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -169.46% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 0.372% |
| Neutra Corp. | 973.52 Thousand USD | -460.601% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 81.19% |
| PureTech Health plc | 125.58 Million USD | 95.654% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -45.26% |
| IXICO plc | 1.9 Million USD | -187.199% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 73.415% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.718% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Cellectis S.A. | 249.36 Million USD | 97.811% |